CAR-T: What’s next? Part 2
In my previous blog post, I suggested that the market size for gene-modified T-cell therapies would be roughly $9 Bn in 10 years, with a...
CAR-T: What’s next? Part 1
Over the last two months, several news events have brought CAR-T cells to widespread public attention, the most prominent of which is the...
Is Digital Health ever going to become mainstream?
I’ve been involved with Digital Health since 2012. At that time, the industry was espousing how Digital Health was ready to explode –...
Pharmacy Benefit Managers (PBMs): Bending the cost curve in the wrong direction
In the NY Times article, “Take the Generic, Patients Are Told. Until They Are Not.”, Pharmacy Benefit Managers (PBMs) were called out for...
